151 results on '"Schepis, F."'
Search Results
2. OC.11.1: UNDERDILATION STRATEGY FOR TIPS PLACEMENT REDUCES INCIDENCE OF OVERT HEPATIC ENCEPHALOPATHY WITHOUT AFFECTING CLINICAL EFFICACY AND SURVIVAL: RESULTS OF A MULTICENTER PROSPECTIVE ITALIAN STUDY
3. BOC.02.7: UNDERDILATED NEOADJUVANT-TIPS IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION CANDIDATES TO OPERATIVE INTERVENTIONS
4. BOC.02.4: EPISODIC OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT DOES NOT INCREASE MORTALITY IN PATIENTS WITH CIRRHOSIS
5. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?
6. Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids
7. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis
8. Response to “Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?”
9. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
10. A machine learning enabled score based on large varices predicts 5- and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with compensated advanced chronic liver disease
11. Serum procalcitonin predicts mortality independently of the presence of ACLF in patients with cirrhosis and ascites hospitalized for suspicious infection and treated with empiric antibiotic therapy
12. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease
13. TIPS under-dilation strategy with new controlled expansion endoprosthesis: A hemodynamic and imaging confirmation of its feasibility
14. Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974, (S0168827821022996), (10.1016/j.jhep.2021.12.022)]
15. Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study
16. The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease.
17. Transjugular intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multicenter retrospective cohort.
18. Underdilated neoadjuvant-TIPS in patients with cirrhosis and portal hypertension candidates to operative interventions
19. External Validation of the ExPeCT TIPS Prediction Model in a North American Cohort
20. First and further liver decompensation in patients with metabolic-dysfunction associated steatotic liver disease: what clinical impact?
21. Underdilation strategy for TIPS placement reduces incidence of overt hepatic encephalopathy without affecting clinical efficacy and survival: results of a multicenter prospective Italian study
22. End-procedural complete haemodynamic response may not be essential for the clinical success of TIPS in patients with cirrhosis
23. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis
24. Corrigendum to 'Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives'
25. Erratum: Alcoholic and nonalcoholic liver disease: Diagnostic assessment and therapeutic perspectives (BioMed Research International (2019) 2019 (8691502) DOI: 10.1155/2019/8691502)
26. Assessment of sarcopenia improves the prediction of post-TIPS mortality in older adult patients with cirrhosis.
27. Predicting post-TIPS hepatic encephalopathy risk in patients with cirrhosis and refractory ascites: a proof-of-concept study using a 4D MRI perfusional model.
28. Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis
29. Systemic inflammation is associated with hyperdynamic circulation and predicts acute-on-chronic liver failure
30. Consensus conference on TIPS management: Techniques, indications, contraindications
31. Retraction: The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD) (Metabolites 2019, 9(2), 25)
32. Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease
33. Clinical presentation and etiological spectrum of idiopathic non-cirrhotic portal hypertension (INCPH): data from the Italian Registry
34. High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis
35. Low Molecular Weight Heparin (LMWH) treatment does not increase the risk of bleeding after prophylactic endoscopic variceal band ligation in patients with cirrhosis
36. Progressive alterations of cardiopulmonary hemodynamics accompanied by increasing levels of C reactive protein (CRP) occur in patients in different stages of cirrhosis and predict death in decompensated cirrhosis
37. Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated Cirrhosis
38. Low Molecular Weight Heparin Treatment Does not Increase the Risk of Bleeding after Prophylactic Endoscopic Variceal Band Ligation in Patients with Cirrhosis
39. The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias
40. SAT-219 - High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis
41. SAT-026 - Low Molecular Weight Heparin Treatment Does not Increase the Risk of Bleeding after Prophylactic Endoscopic Variceal Band Ligation in Patients with Cirrhosis
42. THU-347 - Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated Cirrhosis
43. A New Catheter for Large Veins: A Better Way.
44. Reply
45. Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study
46. Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19
47. Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF)
48. Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus
49. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study
50. Consensus conference on TIPS management: Techniques, indications, contraindications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.